U.S. FDA completes inspection of Lupin's Dabhasa Facility with No Observations

Global pharma major Lupin Limited (Lupin) today announced that the United States Food and Drug Administration (U.S. FDA) has completed a GMP Inspection of its API manufacturing facility located at Dabhasa, India. The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations.

"We are pleased to announce the successful completion of the U.S. FDA inspection of our Dabhasa facility," said Nilesh Gupta, Managing Director, Lupin. "This accomplishment underscores our unwavering dedication to maintaining the highest standards of quality and compliance in all aspects of our operations. This reaffirms our pursuit of excellence in delivering high-quality, affordable healthcare for all."

Shares of Lupin Limited was last trading in BSE at Rs. 1623.30 as compared to the previous close of Rs. 1605.50. The total number of shares traded during the day was 57952 in over 4933 trades.

The stock hit an intraday high of Rs. 1641.80 and intraday low of 1597.85. The net turnover during the day was Rs. 94450844.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 USFDA GMPInspection APIManufacturingFacility Dabhasa India NoObservations